NCT04635735: Phase 1/2: Study of Ipilimumab After Stem Cell Transplantation in People With RRMM

NCT04635735: Phase 1/2: Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma

NCT04635735: Phase 1/2: Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma

This study will test the safety of ipilimumab to see what effects, if any, the drug has when used as maintenance therapy for people with relapsed/refractory multiple myeloma who have received chemotherapy and allogeneic hematopoietic stem cell transplant (AHCT). The investigators also want to find out whether giving ipilimumab after chemotherapy and AHCT is a better way to control the multiple myeloma than chemotherapy and AHCT alone.

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborator

Bristol-Myers Squibb

---

ClinicalTrials.gov Identifier: NCT04635735

Official Title: A Phase I/II Trial of Ipilimumab After CD34-Selected Allogeneic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

First Posted : November 19, 2020

Click here to see details on ClinicalTrials.gov

---

Drug: Ipilimumab

Ipilimumab 3 mg/kg every 3 weeks for 4 doses.

---

Ipilimumab

Ipilimumab (Code C2654)

Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody

BMS-734016

Ipilimumab

ipilimumab

IPILIMUMAB

Ipilimumab Biosimilar CS1002

MDX-010

MDX-CTLA4

Yervoy

---

Locations

United States, New Jersey

United States, New York